|
Dr. Lundström joined Kémia in August, 2002 as Vice President of Biology, with responsibility for characterizing the biological activity of Kémia's lead compounds and establishing their ADME/toxicity profiles. Dr. Lundström most recently headed AstraZeneca's pharmacokinetic program and has 27 years of experience in preclinical drug development. He also has worked as Chief Pharmacist in the pharmaceutics department, National Board of Health and Welfare, Division of Drugs, in Stockholm. Dr. Lundström holds a Ph.D. from the University of Uppsala and completed post-doctoral work as a visiting fellow at the National Institutes of Health in Bethesda, Maryland (Laboratory of Chemistry, National Institute of Arthritis, Metabolic and Digestive Disease). | 